Close

Dr Reddy’s Lab gets emergency use authorisation for Sputnik V in India

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Oncology start-ups urged to apply and accelerate their business with Discovery Spark

Applications open for Discovery Park’s oncology themed ‘Discovery...

2025 AI Trends & Pharma Predictions

As we navigate what the future of healthcare will...

Swiss Airtainer reaches major milestone with successful completion of first 50 commercial shipments

Swiss Airtainer is pleased to announce the successful completion of its first 50 commercial shipments of high-value life science...

Dr. Reddy’s Laboratories Ltd. announced that it has received the permission from the Drug Controller General of India(DCGI)to import the Sputnik vaccine into India for restricted use in emergency situationsas per the provisions of the New Drug and Clincial Trials rules, 2019 under the Drugs and Cosmetics Act

In September 2020, Dr. Reddy’s had partnered with the Russian Direct Investment Fund (RDIF) to conduct the clinical trials of Sputnik Vand distribute the vaccine in India.In addition to the trials conducted in Russia by RDIF. Phase II / III clinical trials of the vaccine were carried out by Dr. Reddy’s in India.

Dr Reddy’s Laboratories co-chairman and managing director GV Prasad said, “We are very pleased to obtain the emergency use authorizationfor Sputnik Vin India. With the rising cases in India, vaccination is the most effectivetool in our battleagainst COVID-19. Thiswill enable us to contribute to our nation’s effort of vaccinatinga signficant proportion of our population.”

Sputnik V is now approved for use in 60countries around the world. Itranks second among coronavirus vaccines globally in terms of the number of approvals issued by government regulators. Sputnik V uses two different vectors for the two shots in a course of vaccination.The efficacy of Sputnik V was determined to be 91.6% as per a published article in the Lancet, one of the world’s oldest and most respected medical journals.

About Dr. Reddy’s:
Dr. Reddy’s Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses -Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products –Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include –USA, India, Russia & CIS countries, and Europe.

Latest stories